



SUPRIYA LIFESCIENCE LTD.

Creating true values that bind global health

Date: May 27, 2022

To,

BSE Limited Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai- 400 001 Scrip Code: 543434	National Stock Exchange of India Limited Exchange Plaza, Plot no. C/1, G Block, Bandra-Kurla Complex Bandra (E), Mumbai - 400 051 NSE Symbol: SUPRIYA
---	---

Dear Sir/Madam,


Subject: Annual Secretarial Compliance Report for the financial year ended March 31, 2022

Pursuant to Regulation 24A of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with SEBI Circular No. CIR/CFD/CMD1/27/2019 dated February 8, 2019, we enclosed herewith Annual Secretarial Compliance Report dated May 27, 2022 issued by Mr. Mahesh Darji, Practicing Company Secretary, for the financial year ended March 31, 2022.

Kindly take the information on record.

Thanking you,

For Supriya Lifescience Ltd



Shweta Singh
Company Secretary & Compliance Officer
Membership No.: A44973

Corporate Office : 207/208, Udyog Bhavan, Sonawala Road, Goregaon (East), Mumbai 400 063, Maharashtra, India.

Tel : +91 22 40332727 / 66942507 | Fax : +91 22 26860011 | GSTIN : 27AALCS8686A1ZX

CIN: L51900MH2008PLC180452 | E-mail: supriya@supriyalifescience.com | Website: www.supriyalifescience.com

Factory

: A-5/2, Lote Parshuram Industrial Area, M.I.D.C., Tal.-Khed, Dist. Ratnagiri, Pin: 415 722, Maharashtra, India.

Tel: +91 2356 272299 | Fax : +91 2356 272178 | E-Mail: factory@supriyalifescience.com

GOVT. RECOGNISED EXPORT HOUSE

**ANNUAL SECRETARIAL COMPLIANCE REPORT
FOR THE FINANCIAL YEAR ENDED 31ST MARCH, 2022**

[Pursuant to Regulation 24A of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015]

To
The Board of Directors,
Supriya Lifescience Limited
207 /208 Udyog Bhavan,
Sonawala Road, Goregaon (East),
MUMBAI – 400063

Dear Sir / Madam,

I, Mahesh Darji, Company Secretary in Practice have examined:

- (a) all the documents and records made available to us and explanation provided by **Supriya Lifescience Limited** (hereinafter called "the Company");
- (b) the filings/ submissions made by the listed entity to the stock exchanges;
- (c) website of the listed entity; and
- (d) other document/ filing, as may be relevant, which has been relied upon to make this certification;

for the financial period ended 31st March, 2022 in respect of compliance with the provisions of:

- (a) the Securities and Exchange Board of India Act, 1992 ("SEBI Act") and the Regulations, circulars, guidelines issued thereunder; and
- (b) the Securities Contracts (Regulation) Act, 1956 ("SCRA"), rules made thereunder and the Regulations, circulars, guidelines issued thereunder by the Securities and Exchange Board of India ("SEBI");



Mahesh M. Darji

Practicing Company Secretary
B.Com., DBM, LLB, FCS

The specific Regulations, whose provisions and the circulars/ guidelines issued thereunder, have been examined, include:

- (a) Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015;
- (b) Securities and Exchange Board of India (Issue of Capital and Disclosure Requirements) Regulations, 2018 (to the extent applicable);
- (c) Securities and Exchange Board of India (Substantial Acquisition of Shares and Takeovers) Regulations, 2011;
- (d) Securities and Exchange Board of India (Prohibition of Insider Trading) Regulations, 2015;
- (e) Securities and Exchange Board of India (Registrars to an Issue and Share Transfer Agents) Regulations, 1993, regarding the Companies Act and dealing with client;
- (f) Securities and Exchange Board of India (Depositories and Participants) Regulations, 2018.

and based on the above examination, we hereby report that, during the financial period ended 31st March, 2022:

- (a) The Company has complied with the provisions of the above Regulations and circulars/ guidelines issued thereunder.
- (b) The listed entity has maintained proper records under the provisions of the above Regulations and circulars/ guidelines issued thereunder insofar as it appears from our examination of those records;
- (c) No actions were taken against the Company/ its promoters/ directors/ material subsidiaries, if any either by SEBI or by Stock Exchanges (including under the Standard Operating Procedures issued by SEBI through various circulars) under the aforesaid Acts/ Regulations and circulars/ guidelines issued thereunder;
- (d) The Company was not required to take corrective action as there were no adverse observations made in previous reports;




Mahesh M. Darji

Practicing Company Secretary
B.Com., DBM, LLB, FCS

- (e) The Company has complied with requirements of para 6(A) and 6(B) of SEBI Circular CIR/CFD/CMD1/114/2019 dated 18th October, 2019 by modifying the terms of appointment of Statutory Auditors.

Due to COVID-19 outbreak and Lockdown situation, we have relied on the information, details, data, documents and explanation as provided by the Company and its officers and agents in electronic form and partially in physical form.

Note: It may be noted that the Company had come out with Initial Public Officer (IPO) during the finance period under review and the Equity Shares of the Company were listed on BSE Limited and National Stock Exchange of India Limited w.e.f 28th December, 2021 and hence the applicability of SEBI Rules, Regulations, Circulars and Notifications as referred in this report be read accordingly.



Mahesh M. Darji
Company Secretary in Practice
FCS: 7175
CP: 7809
Peer Review No. 2061/2022

Place: Mumbai

Date: 27.05.2022

UDIN: F007175D000405804

